Navigation Links
Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
Date:9/25/2008

s Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, failure of Nuvelo or ARCA's stockholders to approve the merger, the ability to complete the transaction contemplated by this communication in a timely fashion, the risk that Nuvelo's and ARCA's business operations will not be integrated successfully; the combined company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the combined company's financial resources will be insufficient to meet the combined company's business objectives; uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10-Q for the quarter ended June 30, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.

Additional Information and Where to Find It

Nuvelo intends to file a registration statement on Form S-4, and a related proxy statement/prospectus, in connection with the merger. Investors and security holders are urged to read the registration statement on Form S-4 and the related proxy statement/prospectus when they become available because they will contain important information about the merger transaction. Investors and security holders may obtain free copies of
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
4. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
5. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
6. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
7. China Biopharma Effects 1 for 100 Reverse Stock Split
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. Therapure Biopharma Inc. opens for business with first client contracts
10. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... San Francisco, CA (PRWEB) April 16, 2015 ... is scheduled to report first quarter results on Thursday, ... the announcement, Cytokinetics’ senior management will host a conference ... and financial results and the company’s outlook for the ... and can be accessed from the homepage and in ...
(Date:4/16/2015)... 16, 2015 According to the ... an outside source was ranked first among the ... related to lifting, pushing, pulling, holding, carrying, or ... costs. The David Round Company takes statistics like ... working hard to develop and design equipment that ...
(Date:4/16/2015)... 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... joint venture with G-treeBNT (ReGenTree LLC) has retained ... trial for the orphan disorder, neurotrophic keratopathy (NK), ... eye syndrome (DES) in the U.S.  Both trials ... this year.  Each of these eye disorders was ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... will receive the Johnson & Johnson Dr. Paul Janssen Award ... a series of events that celebrate his central role in ... signaling molecule of angiogenesis. His research has opened the door ... combat a serious eye disorder and contributed to the development ...
... 13Researchers at Vanderbilt University have developed a new technique that ... tissue at multiple points simultaneously, a method that could help ... and change shape. UV lasers are a commonly-used ... incisions by vaporizing one point at a time in a ...
... 2011 Saladax Biomedical, Inc., a privately held company ... promise of personalized medicine for new and existing therapeutics, ... of Saladax, will be presenting at the Annual UBS ... York in New York City on Tuesday, September 20, ...
Cached Biology Technology:Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research 2Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research 3Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research 4Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research 5Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City 2
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... of poor rice farmers and consumers in Asia have received ... While the world's trading nations remain deadlocked on how to ... farmers of the developing world, research just published has confirmed ... planet's two most populous countries, China and India. , The ...
... damaged heart muscle tissue . . . regenerate injured bone ... . even reverse nerve damage. Human stem cells offer tremendous ... and a variety of other human health problems. , Up ... ethical controversy -- as well as by the rarity of ...
... emerged field of bacterial riboswitches may be a good ... to a report by Yale researchers in the journal ... control gene expression in essential metabolic pathways. Researchers in ... Henry Ford II Professor of Molecular, Cellular and ...
Cached Biology News:Some good news for the world's poor 2Some good news for the world's poor 3Some good news for the world's poor 4From one cell, many possible cures 2From one cell, many possible cures 3Switching to new anti-bacterial targets: Riboswitches 2
... AC is the easiest to program ... provided with liquid level sensors for ... integrated orbital shaker and automatic rinsing ... performance. The big bottle model is ...
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
... Benzonase Nuclease is a genetically engineered endonuclease. ... DNA and RNA while having no proteolytic ... range of conditions and possesses an exceptionally ... nucleic acids from recombinant proteins, its use ...
... genome-wide microRNA expression profiling and built ... microfluidic on-chip synthesis platform. These microarrays ... comprehensive microRNA Expression Profiling Service. ... microRNA Microarray contains all known rice ...
Biology Products: